Given the upregulation of CCN2 in B‐ALL compared to T‐ALL, targeting CCN2 may offer a strategy to mitigate aberrant cellular processes in ALL such as cell proliferation, migration, and adhesion. The gene discussed is CCN2; the disease is acute lymphoblastic leukemia.